News & Views | Telix Pharmaceuticals Limited

First Patient Dosed in Phase II ‘IPAX-Linz’ Study of TLX101 for Glioblastoma Therapy

Telix today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent high-grade gliomas (HGG), including glioblastoma multiforme (GBM).

Telix Acquires Optimal Tracers

Telix today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials.

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of studies evaluating CAIX expression in cancers other than clear cell renal cell carcinoma (ccRCC), supporting Telix’s goal to rapidly expand the CAIX program into other indications beyond kidney cancer.

Telix Reports Third Quarter 2022 Financial Results

Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2022.

TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM

Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of studies evaluating CAIX expression in cancers other than clear cell renal cell carcinoma (ccRCC), supporting Telix’s goal to rapidly expand the CAIX program into other indications beyond kidney cancer.

Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market

Telix Quarterly Results and Investor Call / Webcast Notification

Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

Health Canada Approves Illuccix® for Prostate Cancer Imaging

Telix announces that Health Canada has approved Illuccix® [kit for the preparation of gallium (68Ga) gozetotide injection] for use in staging and re-staging intermediate and high-risk prostate cancer and localizing tumour tissue in recurrent prostate cancer.

First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent

Telix today announces the first commercial dose in New Zealand of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11 injection.